SGS Invests in Genotypic DNA Sequencing System
PTSM: Pharmaceutical Technology Sourcing and Management
The company invested in the MicroSeq Rapid Microbial Identification System from Applied Biosystems at its Illinois facility.
On July 12, 2016, SGS announced that it has invested in a genotypic DNA sequencing MicroSeq Rapid Microbial Identification System from Applied Biosystems at its Chicago, IL facility, located in the suburb of Lincolnshire. The molecular identification system is undergoing validation and is expected to be fully implemented in Q3, thus enabling the site to provide accurate, high-speed microbiological testing for the identification of microorganisms.
The installation and validation of the new genotypic DNA sequencing MicroSeq ID system will minimize transit delays by consolidating testing requirements through a single laboratory, rapidly obtaining identification of bacterial and fungal isolates, and facilitating a rapid response to the investigation of contamination. The investment at SGS’s Chicago site follows recent microbiological testing expansions at the company’s Villeneuve La Garenne, France facility, which provides services to address the growing biopharmaceutical pipeline with capabilities for mycoplasma tests and amino acid analysis, and in Shanghai, China, where a highly active compound laboratory, designed to test products such as antibodies and hormones, is located.
Source: SGS
FDA Approves First Treatment for Rare Lipid Storage Disease Cerebrotendinous Xanthomatosis
February 24th 2025Cerebrotendinous xanthomatosis, or CTX, is a metabolic disorder caused by a gene mutation that results in a deficiency of an important enzyme in the ability of the human body to break down fats.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
